JPWO2019126086A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019126086A5 JPWO2019126086A5 JP2020533847A JP2020533847A JPWO2019126086A5 JP WO2019126086 A5 JPWO2019126086 A5 JP WO2019126086A5 JP 2020533847 A JP2020533847 A JP 2020533847A JP 2020533847 A JP2020533847 A JP 2020533847A JP WO2019126086 A5 JPWO2019126086 A5 JP WO2019126086A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- alkyl
- oxy
- cyclohexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 34
- -1 cyano, hydroxyl Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 25
- 239000012453 solvate Substances 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 125000004103 aminoalkyl group Chemical group 0.000 claims 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 5
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- HANZNSXZJCLSFY-PMACEKPBSA-N (1S,3S)-3-[6-[3-methyl-4-[[(4-phenylpyrimidin-2-yl)amino]methyl]-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1CNC1=NC=CC(=N1)C1=CC=CC=C1)C1=CC=C(C=N1)O[C@@H]1C[C@H](CCC1)C(=O)O HANZNSXZJCLSFY-PMACEKPBSA-N 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000001769 aryl amino group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004992 haloalkylamino group Chemical group 0.000 claims 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- HANZNSXZJCLSFY-UXHICEINSA-N (1R,3S)-3-[6-[3-methyl-4-[[(4-phenylpyrimidin-2-yl)amino]methyl]-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1CNC1=NC=CC(=N1)C1=CC=CC=C1)C1=CC=C(C=N1)O[C@@H]1C[C@@H](CCC1)C(=O)O HANZNSXZJCLSFY-UXHICEINSA-N 0.000 claims 2
- DZOOQPQZZLCXFW-ICSRJNTNSA-N (1S,3S)-3-[6-[3-methyl-4-[[(4-phenoxypyrimidin-2-yl)amino]methyl]-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1CNC1=NC=CC(OC2=CC=CC=C2)=N1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=N1 DZOOQPQZZLCXFW-ICSRJNTNSA-N 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- CLNGSHMXUZUNOH-JTHBVZDNSA-N (1S,3R)-3-[4-[3-methyl-4-[(4-phenylpyrimidin-2-yl)oxymethyl]-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1COC1=NC=CC(=N1)C1=CC=CC=C1)C1=CC=C(O[C@H]2C[C@H](CCC2)C(=O)O)C=C1 CLNGSHMXUZUNOH-JTHBVZDNSA-N 0.000 claims 1
- CLNGSHMXUZUNOH-GMAHTHKFSA-N (1S,3S)-3-[4-[3-methyl-4-[(4-phenylpyrimidin-2-yl)oxymethyl]-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1COC1=NC=CC(=N1)C1=CC=CC=C1)C1=CC=C(O[C@@H]2C[C@H](CCC2)C(=O)O)C=C1 CLNGSHMXUZUNOH-GMAHTHKFSA-N 0.000 claims 1
- FHWCWPKMPYJKLZ-VXKWHMMOSA-N (1S,3S)-3-[6-[3-methyl-4-[[(4-phenylpyridin-2-yl)amino]methyl]-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1CNC1=NC=CC(=C1)C1=CC=CC=C1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=N1 FHWCWPKMPYJKLZ-VXKWHMMOSA-N 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 1
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607398P | 2017-12-19 | 2017-12-19 | |
| US62/607,398 | 2017-12-19 | ||
| PCT/US2018/066111 WO2019126086A1 (en) | 2017-12-19 | 2018-12-18 | Cyclohexyl acid isoxazole azines as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506878A JP2021506878A (ja) | 2021-02-22 |
| JPWO2019126086A5 true JPWO2019126086A5 (enrdf_load_stackoverflow) | 2022-01-31 |
| JP7526096B2 JP7526096B2 (ja) | 2024-07-31 |
Family
ID=65003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533847A Active JP7526096B2 (ja) | 2017-12-19 | 2018-12-18 | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11319309B2 (enrdf_load_stackoverflow) |
| EP (1) | EP3728209A1 (enrdf_load_stackoverflow) |
| JP (1) | JP7526096B2 (enrdf_load_stackoverflow) |
| KR (1) | KR102828422B1 (enrdf_load_stackoverflow) |
| CN (1) | CN111479807B (enrdf_load_stackoverflow) |
| WO (1) | WO2019126086A1 (enrdf_load_stackoverflow) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP3728222B1 (en) * | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| CN112189010A (zh) | 2017-12-19 | 2021-01-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
| EP3852746B1 (en) | 2018-09-18 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| JP2023505702A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのチエノピリミジン誘導体 |
| WO2021116259A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| CN114786771A (zh) | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| JP2023533851A (ja) | 2020-07-16 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体阻害剤としてのアミドシクロヘキサン酸誘導体 |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| JP2024512557A (ja) | 2021-03-24 | 2024-03-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US20250066341A1 (en) | 2021-12-23 | 2025-02-27 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| CN119095831A (zh) * | 2022-03-25 | 2024-12-06 | 瓦斯塞拉股份有限公司 | 3-苯基异噁唑衍生物和含有其作为活性成分的用于预防或治疗眼部疾病的药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137405D1 (de) | 2000-02-18 | 2009-03-05 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| JP4396808B2 (ja) | 2001-02-08 | 2010-01-13 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤 |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| CN102574822A (zh) * | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CA2820817A1 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| CN103443098B (zh) | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) * | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| SG11201407228PA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-aryltriazole compounds as lpar antagonists |
| EA201492285A1 (ru) | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN112189010A (zh) | 2017-12-19 | 2021-01-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
-
2018
- 2018-12-18 JP JP2020533847A patent/JP7526096B2/ja active Active
- 2018-12-18 CN CN201880080917.3A patent/CN111479807B/zh active Active
- 2018-12-18 EP EP18830677.3A patent/EP3728209A1/en active Pending
- 2018-12-18 US US16/954,552 patent/US11319309B2/en active Active
- 2018-12-18 KR KR1020207020554A patent/KR102828422B1/ko active Active
- 2018-12-18 WO PCT/US2018/066111 patent/WO2019126086A1/en not_active Ceased